PGLYRP1

Across TCGA pan-cancer cohorts, PGLYRP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PGLYRP1 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PGLYRP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PGLYRP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, HNSC, and ESCA are the cancer types where PGLYRP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.001	33	view →
HNSC	DFS	Median	All	0.195	0.710	.019	18	view →
ESCA	OS	Median	II,III,IV	0.226	0.686	.013	12	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.629	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PGLYRP1–STAD (OS)

Open the STAD breakdown →